Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2023-04-28 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
中国际金融股份有限公司关于成都先导药物开发股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion from a sponsoring institution (China International Capital Corporation) regarding the use of temporarily idle raised funds by Chengdu Lead Pharma Co., Ltd. for cash management. It references regulatory guidelines on the management and use of raised funds, details the amount, investment products, risk controls, and approvals by the board and independent directors. The document is not a financial report itself but a regulatory compliance and verification opinion related to the use of raised funds. It does not contain financial statements or earnings data. The document length is under 5,000 characters and is a formal verification and opinion letter, not an announcement of a report publication. This fits best under Regulatory Filings (RNS) as it is a compliance-related regulatory document that does not fit other categories like Capital/Financing Update (CAP) because it is about cash management of raised funds rather than new financing, nor is it an Audit Report or Annual Report. Therefore, the classification is Regulatory Filings (RNS).
2023-04-28 Chinese
成都先导药物开发股份有限公司关于持股5%以上股东减持达到1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement regarding a shareholder's reduction in holdings exceeding 1%, specifically disclosing details about the shareholding changes of shareholders holding more than 5% of the company's shares. It includes information about the shareholders, the number of shares reduced, the method of reduction, and confirms that the reduction does not affect control or governance. The document is titled as a "提示性公告" (prompting announcement) about shareholding changes and does not contain financial statements or detailed financial analysis. It is not a full financial report, earnings release, or management discussion. It fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2023-04-19 Chinese
成都先导药物开发股份有限公司关于股东深圳市钧天投资企业（有限合伙）、钧天创业投资有限公司减持数量过半暨减持股份进展公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the reduction of shareholding by specific shareholders (Shenzhen Juntian Investment Enterprise and Juntian Venture Capital Co., Ltd.) in Chengdu Lead Drug Development Co., Ltd. It details the number of shares held before and after the reduction, the methods of reduction (centralized bidding and block trades), the timeline, and the impact on company control and governance. There is no financial statement, no discussion of company financial performance, no management commentary on results, no legal proceedings, no merger or acquisition activity, and no mention of an annual or interim report. The document is a formal disclosure of a shareholder's reduction in holdings, which fits the definition of a Major Shareholding Notification (MRQ). The document length is 2245 characters, which is relatively short but contains substantive information about shareholding changes, not just an announcement of a report publication or a certification. Therefore, the correct classification is MRQ with high confidence.
2023-04-18 Chinese
成都先导药物开发股份有限公司关于持股5%以上股东减持达到1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement from Chengdu Lead Drug Development Co., Ltd. regarding a shareholder holding more than 5% reducing their stake by 1%. It details the shareholding changes, dates, and legal compliance statements. There is no financial data, earnings information, or report attached. The content fits the definition of a Major Shareholding Notification, which involves notifying changes in significant share ownership levels crossing thresholds. The document length is short and focused solely on shareholding changes, not a full report or announcement of a report publication.
2023-04-07 Chinese
成都先导药物开发股份有限公司首次公开发行限售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares following the company's initial public offering (IPO). It details the number of shares becoming freely tradable, lock-up periods, shareholder commitments, and regulatory compliance confirmations. The document references regulatory approvals and contains no financial statements or earnings data. It is a formal disclosure about share circulation and shareholder commitments rather than a financial report or earnings release. This fits the category of a Regulatory Filing (RNS), as it is a regulatory announcement about share circulation and shareholder commitments without substantive financial data or report content.
2023-04-07 Chinese
中国国际金融股份有限公司关于成都先导药物开发股份有限公司首次公开发行限售股上市流通的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a financial institution regarding the unlocking and circulation of restricted shares following an initial public offering (IPO) of Chengdu Lead Drug Development Co., Ltd. It references regulatory approvals, lock-up periods, shareholder commitments, and compliance with securities laws. The content focuses on the status and conditions of restricted shares becoming tradable, including shareholder commitments and lock-up expiration dates. This type of document is typically a formal verification or audit opinion related to share issuance and circulation, not a full annual or quarterly report, earnings release, or management discussion. It is not a simple announcement or a proxy statement. Given the detailed verification and compliance nature, this fits best under Audit Report / Information (AR), which includes standalone audit reports and regulatory compliance verifications related to share issuance and stock circulation. Q2 2023
2023-04-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.